Long-term Data Collection for Subjects in MDX-010 Studies
NCT00928031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2010-04-26
Summary
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Walter Urba, MD PhD · Providence Health & Services
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-06-30
- Primary Completion
- 2009-04-30
- Completion
- 2009-04-30
Countries
- United States
Study Locations
More Related Trials
-
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
NCT02374242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
NCT00623766 ·Status: COMPLETED ·Phase: PHASE2
-
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
NCT03438279 ·Status: COMPLETED
-
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT02581930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
NCT02816021 ·Status: COMPLETED ·Phase: PHASE2
-
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
NCT00162123 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
NCT00261365 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
NCT00289627 ·Status: COMPLETED ·Phase: PHASE2
-
Axitinib + Ipilimumab in Advanced Melanoma
NCT04996823 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1
-
Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
NCT02673970 ·Status: RECRUITING
-
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma
NCT00920907 ·Status: COMPLETED ·Phase: PHASE1
-
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
NCT01654692 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
NCT00790010 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
NCT01689870 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
NCT02780089 ·Status: COMPLETED
-
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
NCT00135408 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
NCT01515189 ·Status: COMPLETED ·Phase: PHASE3
-
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
NCT01323517 ·Status: COMPLETED ·Phase: PHASE2